0000904454-13-001086.txt : 20131003 0000904454-13-001086.hdr.sgml : 20131003 20131003182206 ACCESSION NUMBER: 0000904454-13-001086 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131001 FILED AS OF DATE: 20131003 DATE AS OF CHANGE: 20131003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA GENETICS INC CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4105 E MADISON STREET STREET 2: SUITE 320 CITY: SEATTLE STATE: WA ZIP: 98112 BUSINESS PHONE: 206 325 6086 MAIL ADDRESS: STREET 1: 4105 E MADISON STREET STREET 2: SUITE 320 CITY: SEATTLE STATE: WA ZIP: 98112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chen Shu-Chih CENTRAL INDEX KEY: 0001552127 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 131134993 MAIL ADDRESS: STREET 1: C/O ATOSSA GENETICS, INC STREET 2: 4105 E MADISON STREET, SUITE 320 CITY: SEATTLE STATE: WA ZIP: 98112 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2013-10-01 0001488039 ATOSSA GENETICS INC ATOS 0001552127 Chen Shu-Chih 4105 E. MADISON STREET, SUITE 320 SEATTLE WA 98112 1 1 1 0 Chief Scientific Officer Common Stock 2013-10-01 4 S 0 7265 5.658 D 4268315 I By Ensisheim Partners, LLC The sales reported on this Form 4 were effected pursuant to a trading plan previously adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The trading plan was previously reviewed and approved by the Company's board of directors in accordance with Rule 10b5-1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.57 to $5.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Ensisheim Partners, LLC is wholly owned by the Reporting Person and Dr. Steven Quay, the Chief Executive Officer of the Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of all such securities for purposes of Section 16 or any other purpose. /s/ Shu-Chih Chen 2013-10-03